Roivant Subsidiary Reaches Major Global Patent Settlement

Roivant Sciences ( (ROIV) ) has provided an update.

On March 3, 2026, Roivant’s subsidiary Genevant Sciences and partner Arbutus Biopharma reached a $2.25 billion global settlement with Moderna to resolve all U.S. and international patent litigation over Moderna’s use of their lipid nanoparticle delivery technology in COVID-19 vaccines, including Spikevax. The deal includes a $950 million upfront payment due by July 8, 2026, a further contingent payment of up to $1.3 billion linked to the outcome of Moderna’s appeal on Section 1498, and Moderna’s consent to judgments of infringement and no invalidity on four patents.

As part of the settlement, Genevant and Arbutus will grant Moderna a fully paid-up, royalty-free, irrevocable global non-exclusive license and covenant not to sue covering SM-102-based LNP formulations in certain mRNA infectious-disease vaccines, ending all related patent disputes between the parties. Roivant highlighted that, if fully realized, this would be one of the largest patent settlements in the pharmaceutical sector, bolsters the credibility of its LNP intellectual property amid ongoing Pfizer/BioNTech litigation, and supports capital allocation moves such as a $1 billion share repurchase program approved by its board.

The most recent analyst rating on (ROIV) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.

Spark’s Take on ROIV Stock

According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.

The score reflects a strong strategic outlook from the earnings call (multiple upcoming readouts, positive clinical data, and substantial cash runway) and supportive price trend, partially offset by weak financial performance driven by ongoing losses and cash burn and a weak valuation profile due to negative earnings and no dividend.

To see Spark’s full report on ROIV stock, click here.

More about Roivant Sciences

Roivant Sciences is a biopharmaceutical company that accelerates the development and commercialization of medicines through a portfolio of “Vant” subsidiaries focused on specific therapies and technologies. Its pipeline spans autoimmune and inflammatory diseases and pulmonary hypertension, and it also incubates discovery-stage biotechs and health technology ventures complementary to its core drug development business.

Genevant Sciences, a Roivant subsidiary, is a leading nucleic acid delivery specialist with a broad lipid nanoparticle patent estate underlying numerous RNA-based applications, including vaccines and gene editing. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, notably chronic hepatitis B, and collaborates closely with Genevant to enforce and defend their shared LNP intellectual property.

Average Trading Volume: 7,054,781

Technical Sentiment Signal: Buy

Current Market Cap: $20.11B

See more insights into ROIV stock on TipRanks’ Stock Analysis page.